Table 2.
Validation cohort participant characteristics
| Characteristics | Total (N = 95) |
|---|---|
| Sex | |
| Female | 47 (49%) |
| Male | 48 (51%) |
| Age (years) | |
| Median [minimum, maximum] | 59.0 [18.0, 84.0] |
| Diagnosis | |
| AML | 95 (100%) |
| Tumor cell infiltration | |
| Median [minimum, maximum] | 76.0 [50.0, 99.0] |
| Prescribed treatment | |
| Cytarabine + daunorubicin | 95 (100%) |
| In vivo response group | |
| Non-responder | 48 (51%) |
| Responder | 47 (49%) |
| ELN-22 risk group | |
| Adverse | 36 (38%) |
| Favorable | 16 (17%) |
| Intermediate | 43 (45%) |
Data are number of participants (%) or median [range]. Percentages may not total 100 because of rounding.